BLUE - Bluebird bio Inc
(NaN%)
Sell
Gross Profit was Negative
16%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 126.99%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -192.39%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 0.55
Debt Ratio is 1.2
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.49
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Bluebird bio Inc (BLUE) - bluebirdbio.com
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO -
Employees - 733
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.